MPG.eBooks - Search Results

21

Patient group input submissions: Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or photothe...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

22

Patient group input submissions: Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited)

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

23

CADTH Canadian Drug Expert Committee final recommendation: Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

24

Pharmacoeconomic review report: Ocrelizumab (Ocrevus) (Hoffmann-La roche limited)

Published 2017

CADTH

Subjects: “...Canada...”

Read Now

25

Pharmacoeconomic review report: Sarilumab (Kevzara)

Published 2017

CADTH

Subjects: “...Canada...”

Read Now

26

CADTH Canadian Drug Expert Committee recommendation: Dupilumab (Dupixent -- Sanofi-Aventis Canada Inc.) : indication: atopic dermatitis

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

27

Clinical review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication : for the treatment of adult patients with active ankylosing spondylitis who have responded inadequa...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

28

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Canada...”

Read Now

29

CADTH Canadian Drug Expert Committee recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: ankylosing spondylitis

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

30

CADTH Canadian Drug Expert Committee recommendation: Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis

Published 2018

CADTH

Subjects: “...Canada...”

Read Now

31

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

32

CADTH Canadian Drug Expert Committee final recommendation: Ixekizumab (Taltz -- Eli Lilly Canada Inc.) : indication: moderate to severe plaque psoriasis

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

33

Pharmacoeconomic review report: Ixekizumab (Taltz) (Eli Lilly Canada Inc.) : indication: for the treatment of adult patients with active ankylosing spondylitis who have responded i...

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

34

High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Wells, Charlotte, Grobelna, Aleksandra
Published 2019

CADTH

Subjects: “...Canada...”

Read Now

35

High dose influenza vaccine for adults : a review of clinical effectiveness, cost-effectiveness, and guidelines

by Wells, Charlotte, Grobelna, Aleksandra
Published 2019

CADTH

Subjects: “...Canada...”

Read Now

36

Pharmacoeconomic review report: Belimumab (Benlysta) (GlaxoSmithKline Inc.) : indication: indicated in addition to standard therapy for reducing disease activity in adult patients...

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

37

Pharmacoeconomic report: Vedolizumab (Entyvio SC) Takeda Canada Inc. : indication : for the treatment of adult patients with moderately to severely active ulcerative colitis who ha...

Published 2020

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

38

CADTH Canadian Drug Expert Committee recommendation: Belimumab (Benlysta subcutaneous [SC] -- GlaxoSmithKline Inc.) : indication: systemic lupus erythematosus (SLE)

Published 2020

CADTH

Subjects: “...Canada...”

Read Now

39

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Read Now

40

CADTH Canadian Drug Expert Committee recommendation: Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

Published 2017

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Canada...”

Narrow Search